Welcome to our dedicated page for HNSA news (Ticker: HNSA), a resource for investors and traders seeking the latest updates and insights on HNSA stock.
Hansa Biopharma (HNSA) is a leader in developing IgG-cleaving enzyme therapies for complex immunological challenges. This page provides essential updates on clinical advancements, regulatory milestones, and strategic initiatives across transplantation, autoimmune diseases, and gene therapy applications.
Investors and researchers will find comprehensive coverage of HNSA's progress with IDEFIRIX commercialization, next-generation candidates like HNSA-5487, and pivotal trials addressing anti-GBM disease and transplant desensitization. Our curated news collection enables efficient tracking of scientific breakthroughs and market developments.
Key updates include clinical trial results, partnership announcements with gene therapy innovators, financial performance reports, and regulatory submissions. All content is verified through primary sources to ensure accuracy and current relevance.
Bookmark this page for structured access to HNSA's evolving therapeutic pipeline and scientific leadership in antibody-mediated conditions. Regular updates reflect the company's commitment to transforming treatment paradigms through targeted enzyme technology.
Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will release its interim report for January-March 2023 on April 20, 2023, at 8:00 CET. Following the report, a telephone conference hosted by CEO Søren Tulstrup and CFO Donato Spota will take place at 14:00 CET (8:00 AM EST) to discuss the results and provide a business update. Interested participants can access the call using the provided dial-in numbers from Sweden, the UK, and the US. The presentation slides will be available on the company's website during the call and online afterward. Key upcoming financial events include the Redeye Investor Forum and the Half-year report on July 20, 2023. For more information, contact Klaus Sindahl or Stephanie Kenney.
Hansa Biopharma has completed enrollment for its phase 2 study of imlifidase in patients with Guillain-Barré Syndrome (GBS). This study, conducted across the UK, France, and the Netherlands, assesses the safety and efficacy of imlifidase alongside standard treatment. Top-line data is anticipated in the second half of 2023, with a comparative analysis with the International Guillain-Barré Syndrome Outcome Study cohort planned for 2024. GBS affects 1-2 in 100,000 people yearly and can lead to severe disability. Imlifidase previously received Orphan Drug Designation from the FDA for GBS treatment in 2018.
Hansa Biopharma (HNSA) announced on March 29, 2023, that the Spanish Minister of Health granted reimbursement for Idefirix®, an innovative treatment for desensitizing highly sensitized adult patients before kidney transplants. This decision follows its conditional approval by EMA in August 2020. With approximately 20% of nearly 4,000 kidney transplant waitlist patients in Spain being highly sensitized, this approval allows for greater access to potentially lifesaving transplants. Now available in five key Western European countries, Idefirix® addresses a significant unmet medical need for these patients.
